Background: Few studies have analized the persistence of ultrasound (US) abnormalities in patients (pts) with Psoriatic Artritis (PA) during the phase of minimal disease activity (MDA) Objectives: To investigate the prevalence of US alterations at enthesis, joint and tendon levels in pts with psoriatic arthritis (PA) during a phase of MDA. Methods: Pts treated with anti-tumor necrosis factor (TNF) for at least 12 months and with at least 6 months duration of MDA were consecutively recruited at 6 Italian centers. In every center, the local rheumatologists provided PA pts to be examined by US. Personal history, demographic and clinical data were recorded. Each patient underwent the following US examinations: metacarpophalangeal (MCP), knee and tibio-tarsal (TT) joint, flexor and extensor tendon of hand digit, flexor and extensor tendon at carpal area, flexor and extensor tendon of foot, and enthesis of common extensor tendon insertion on the lateral epicondyle of the humerus, quadriceps tendon, patellar tendon, Achilles tendon and plantar fascia insertions on the calcaneus. Each examination were performed by rheumatologists expert in US, to assess synovitis (joint effusion, synovial proliferation, and power Doppler (PD) signal), and bone erosions, flexor tendon tenosynovitis, hand finger extensor tendon tenonitis, and enthesel involvement using an Esaote MyLabClass with a 5-13 or 6-18 MHz linear probe. The following elementary lesions were assessed at each enthesis: morphologic abnormalities (hypoechogenicity and/or thickening), entheseal calcific deposits, cortical abnormalities (bone erosion and/or proliferation), adjacent bursitis and intraenthesis and perienthesis (tendon body and/or bursa) PD signal. All US findings were scored using a 4 degree semiquantitative scoring system. US acute enthesitis was defined by the presence of entheseal edema or PD signal. US chronic entheseal alterations by the presence of calcifications, erosions, or enthesophytes. US peripheral active synovitis if synovial hypertrophy was associated with the presence of PD signal. US examinator were blind of clinical data of the pts. Results: Sixty-three pts were recruited (mean age 53±13y, mean PA duration 13±8y, mean MDA duration 21±11m). At US examination 66.7% of pts had at least one peripheral joint involved (17.5% had peripheral active synovitis), 47.6% had acute enthesitis and 95.2% chronic enthesopathy. US bursitis was present in 22.2% of pts, 3.7% had hand extensor finger tendon involvement. 
Objectives:
The aims of the present study were to evaluate the prevalence of VLDA in patients with PsA and how much residual active disease is still present, so as to determine whether PsAID could be an additional useful tool to assess PsA interventions in clinical practice. Methods: This was a post-hoc analysis of data from a cross-sectional observational and multicenter study (MAAPS), aimed at evaluating the prevalence of MDA in a Spanish population with PsA, to describe their characteristics and to evaluate the association between MDA and the impact of the disease as assessed by the PsAID questionnaire in routine clinical practice The original study included adult patients of both genders diagnosed with PsA according to CASPAR criteria with at least one year of evolution time of disease and on treatment with biological and/or conventional synthetic disease modifying anti-rheumatic drugs (cDMARD). Patients were considered in VLDA when they met all the MDA criteria 1 : tender joint count ≤1, swollen joint count ≤1, Psoriasis Area Severity index (PASI) score ≤1 or body surface area ≤3%, patient pain visual analog scale (VAS) score ≤15, patient global disease activity VAS score ≤20, Health Assessment Questionnaire (HAQ) score ≤0.5, and tender entheseal points ≤1. Patient acceptable symptoms state (PASS) has been defined as a PsAID value <4. Results: 227 patients were included, 133 (58.6%) in MDA state and 58 (25.6%) in VLDA state. VLDA patients suffered from a mild impact of the disease according to PsAID: the majority (82.5%) had a PsAID score <4 and a mean total score (SD) of 2.1 (2.6) IC95% [1.55-2.64], while, 66.7% of MDA patients had a PsAID score <4 and a mean total score (SD) of 3. Background: Psoriatic arthritis (PsA) is a chronic inflamatory disease characterized with axial and peripheral joints involvement. It is rarely affects patients older than 65 years old. Objectives: The purpose of this study is to compare and evaluate the demographic, clinical and laboratory features of elderly-onset psoriatic arthritis (EOPsA) and young-onset (YOPsA) patients. Methods: One hundred and eighty patients diagnosed with PsA according to CASPAR criteria and followed-up in single center were included in this study. The patients with initial symptoms started after age 65 were accepted as EOPsA. Demographic, clinical, and laboratory data and the medications which the patients recieved were recorded and retrospectively evaluated. Results: Nineteen (10.5%)of 180 patients were diagnosed as EOPsA, and 161 (89.5%) patients were evaluated as YOPsA. Mean patient age was 42.1years for YOPsA group and 68.3years for elderly onset group. Mean duration of disease was 5.6 years for early onset group and 1.3 years for elderly onset group (p=0.001). Fourteen (73.3%) of 19 EOPsA patients were female and 5 of them were male. Higher rates of fatique, pain scores, comorbid diseases and acute phase reactants were detected in EOPsA patients comparing to YOPsA (p=0.000, p=0.000, p=0.001 and p=0.001 respectively). YOPsA patients have more dactilitis, nail involvement, elevated PASI scores, and smoking habitus when compared with EOPsA patients (p=0.019, p=0.03, p=0.005, p=0.004 respectively). In terms of the treatment options chosen, there was no significant difference in the use of non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids (CS), methotrexate (MTX), and sulfasalazine (SSL), but there was a more frequent use of anti-tumor necrosis factor -alpha in YOPsA group. Background: Conventionally, the assessment of affected joint count in patients with psoriatic arthritis (PsA) was relied for the detection of swelling and tenderness in the joints and enthesis by clinical physical assessment. To date, the modern imaging tool such as ultrasound (US) can detect inflammation in the joint and enthesis more sensitively than clinical assessment. Objectives: The aim of this study was to research the prevalence of US syovitis and enthesitis findings in patients with PsA and psoriasis (PsO) comparing with clinical assessment. Methods: Total 100 patients, 54 patients with PsA and 46 patients with PsO, were consecutively included. HI VISION Ascendus (HitachiAloka Medical, Tokyo, Japan) was used with a 18-MHz linear array transducer. US examination was performed in MCP, PIP, DIP and wrist joints in both hand. Grayscale (GS) and power Doppler (PD) US were scored on a 0-3 semiquantitative scale for each joint. Moreover, the US assessment of enthesis was performed. Lateral epicondyle, triceps enthesis, the proximal and distal patella tendon enthesis, Achilles tendon and fascia plantaris tendon enthesis was scanned in both GS and PD assessment. Abnormal findings of enthesis was defined structure thickness, bursitis erosion, calcification and power Doppler signal. Results: US synovitis was found in 81.5% (n=44) and 60.9% (n=28) by GS, 66.7% (n=36) and 45.7% (n=21) by PD assessment, respectively in patients with PsA and PsO. Active synovitis (GS grade 2 and/or PD grade 1) was found 
Conclusions

